Free Trial
NASDAQ:IMRX

Immuneering Q3 2023 Earnings Report

Immuneering logo
$186.71 -3.95 (-2.07%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$187.74 +1.03 (+0.55%)
As of 04/17/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Danaher Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Danaher Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
3:00AM ET

Upcoming Earnings

Immuneering's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Danaher Earnings Headlines

Can you still profit from AI this year? (Read this ASAP)
AI isn’t dead — it’s just getting started. Weiss Ratings — ranked #1 by both the SEC and the Wall Street Journal — just issued 3 new “Buy” signals on under-the-radar AI stocks. See the names and ticker symbols now (for free).
Immuneering appoints Matushansky as Chief Medical Officer
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Danaher? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Danaher and other key companies, straight to your email.

About Danaher

Danaher (NYSE:DHR), founded in 1984 by brothers Stephen and Mitchell Rales, is a globally diversified conglomerate headquartered in Washington, D.C. The company has evolved into a major player across various industries, offering a wide range of products and services in the medical, industrial, and commercial sectors. Danaher's mission is to innovate and provide high-quality solutions that positively impact people's lives worldwide. Danaher's began in 1984 as a Massachusetts real estate investment trust called DMG, Inc. The company underwent several reorganizations and strategic acquisitions, culminating in its present-day structure and diverse product portfolio.

Danaher is involved in designing, manufacturing, and marketing a broad array of products and services. Its offerings span medical diagnostics equipment, life sciences and diagnostics tools, environmental solutions, water quality analysis systems, industrial automation tools, and other specialized instruments. Danaher's mission is to leverage its technological expertise and commitment to continuous improvement to develop innovative solutions that enhance human well-being and drive sustainable growth.

The company's diverse product portfolio includes cutting-edge medical diagnostic devices, scientific instruments used in research and healthcare settings, water quality monitoring systems, and automation equipment for industrial applications. Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation. Its products and services find applications in research institutions, healthcare facilities, industrial manufacturers, and government organizations.

Danaher Corporation boasts a leadership team comprising highly accomplished individuals with diverse expertise, driving the company's success and strategic direction. At the helm is Steven M. Rales, the Co-Founder and Chairman, who played a pivotal role in establishing Danaher and has been instrumental in shaping its strategic vision. With his visionary approach, Rales has steered the company towards sustained growth and innovation. Rainer M. Blair holds the positions of President, Chief Executive Officer, and Director, leading Danaher's day-to-day operations and spearheading its growth strategies. Blair's dynamic leadership has been crucial in driving the company's expansion and ensuring its position as a market leader.

Danaher has displayed excellent financial performance in recent years, with consistent revenue growth and profitability. The company's financial stability and strategic acquisitions have contributed to its robust performance. Danaher's strong financials indicate its ability to generate revenue and profits, which has positively influenced investor sentiment and contributed to its favorable valuation.

Danaher's valuation metrics demonstrate positive investor sentiment and confidence in the company's future growth prospects. Its favorable price-to-earnings ratio and price-to-cash flow ratio reflect investor willingness to pay a premium for its earnings potential and cash generation capacity. Danaher's stock performance has been noteworthy, driven by its strong financials, strategic initiatives, and positive market sentiment.

Investors should closely monitor any recent news or events that may have impacted Danaher's share price, such as industry developments or major acquisitions. Danaher operates in diverse industries with various competitors. Its competitive advantages, including a broad product portfolio and emphasis on innovation, position it well within its industries.

Danaher has ample growth opportunities, including expansion into emerging markets, strategic acquisitions, and research and development investments. The company's strong focus on continuous improvement and customer-centric solutions will drive its pursuit of growth opportunities.

Danaher faces potential risks and challenges, including market fluctuations, regulatory changes, and economic uncertainties. However, its proactive risk management strategies mitigate potential impacts on the company's financial performance.

View Danaher Profile

More Earnings Resources from MarketBeat